Nexpoint Asset Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Nexpoint Asset Management’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-12,060	Closed	-$1.59M	–	218
2020 Q4	$1.59M	Buy	+12,060	New	+$1.07M	0.52%	45

Nexpoint Asset Management's EIDX Position: Q1 2021 in Review

Nexpoint Asset Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 12,060 shares — an estimated $1.59M sold.

Nexpoint Asset Management first reported a position in EIDX in Q4 2020 and held it in 1 quarter. The position peaked at $1.59M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Nexpoint Asset Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Nexpoint Asset Management sold 12,060 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $1.59M.
Nexpoint Asset Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Nexpoint Asset Management's Eidos Therapeutics, Inc. Common Stock position peaked at $1.59M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Nexpoint Asset Management's 13F filing for Q1 2021, filed 17 May 2021.